EGFR and neoplasm: Genomic analyses have demonstrated multiple abnormalities such as activating kinase mutations in EGFR and PDGFRA in malignant glioma, but the success of targeted therapy has been limited to date, which may be at least in part due to tumor heterogeneity (Paolillo et al., 2018).